What's Happening?
The field of preclinical drug development is witnessing a shift from traditional animal models to New Approach Methodologies (NAMs). NAMs encompass a range of human-relevant technologies, including in vitro, in silico, and in chemico approaches, such
as organoids and organ-on-chip systems. This transition is driven by the need to bridge the translational gap, as many drugs that perform well in animal models fail in human trials. NAMs offer more predictive insights into human biology, potentially improving the success rate of drug development.
Why It's Important?
The adoption of NAMs could revolutionize drug development by providing more accurate predictions of human responses, reducing the reliance on animal testing, and potentially lowering costs. This shift is crucial for the pharmaceutical industry, as it seeks to improve the efficiency and effectiveness of drug development pipelines. The use of NAMs aligns with ethical considerations by minimizing animal use and could lead to faster, more reliable drug approvals, benefiting patients and healthcare systems.
